Medicine and Dentistry
Acute Myeloid Leukemia
100%
Fibroblast Growth Factor 2
23%
Hematologic Malignancy
20%
Overall Survival
18%
Drug Response
18%
Venetoclax
17%
Chronic Myelogenous Leukemia
16%
Myelodysplastic Syndrome
16%
Acute Promyelocytic Leukemia
16%
Ex Vivo
15%
Risk Stratification
15%
Leukemia
14%
Functional Genomics
13%
Acute Myelogenous Leukemia
13%
Tyrosine-Kinase Inhibitor
13%
Leukemia Cell
13%
Disease
12%
Diagnosis
12%
Next Generation Sequencing
10%
Ivosidenib
10%
Personalized Medicine
10%
Phosphotransferase
9%
Quizartinib
9%
Enasidenib
9%
DNA Methyltransferase 3A
9%
Hematopoietic Stem Cell Transplantation
8%
Combination Drug
8%
Mediastinal Germ Cell Tumor
8%
Ponatinib
8%
Exosome
8%
Hematopoietic Stem Cell
8%
Long Chain Fatty Acid Coenzyme A Ligase
8%
Chromosomal Localization
8%
Proteomics
8%
Point Mutation
8%
Cholesterol Esterification
8%
Spliceosome
8%
Chronic Myelomonocytic Leukemia
8%
Chronic Graft Versus Host Disease
8%
Bone Marrow Stromal Cell
8%
Janus Kinase
8%
Glutathione Reductase
8%
Electrodermal Response
8%
Isocitrate Dehydrogenase Inhibitor
8%
Sulfhemoglobinemia
8%
Pracinostat
8%
Immunosuppressive Treatment
8%
Hematopoiesis
8%
Cell Transplantation
8%
Protein Tyrosine Kinase
8%
Biochemistry, Genetics and Molecular Biology
Myeloid
67%
Proteogenomics
41%
Proteomics
28%
Drug Response
26%
DNMT3A
16%
Imatinib
16%
Chromosomal Localization
16%
Basic Fibroblast Growth Factor
14%
Transcriptomics
13%
Cytogenetics
13%
Phosphoproteomics
13%
Drug Sensitivity
13%
Overall Survival
12%
Next Generation Sequencing
11%
Epidermal Growth Factor Receptor
11%
Functional Genomics
11%
NPM1
10%
Arachidonic Acid
10%
Enzyme
10%
Drug Resistance
10%
Metabolomics
10%
Tyrosine Kinase Inhibitor
8%
Clinical Trial
8%
Long-Chain-Fatty-Acid-CoA Ligase
8%
Adenomatous Polyposis Coli
8%
Calreticulin
8%
Cholesterol Esterification
8%
Point Mutation
8%
Tumor Progression
8%
Cyclooxygenase
8%
Monocyte
8%
IC50
8%
IDH1
8%
Wart Virus
8%
Stromal Cell
8%
Prostaglandin
8%
Spliceosome
8%
Cytotoxicity
8%
Receptor Tyrosine Kinase
8%
Gene Mutation
8%
Genetics
8%
Kinase
7%
Phosphotransferase
7%
High Risk Population
7%
Acetylation
6%
Histone Acetylation
6%
Secretion (Process)
6%
Eicosanoid Receptor
5%
Lipid
5%
Aurora B Kinase
5%
Keyphrases
Acute Myeloid Leukemia
70%
Leukemia Patients
24%
Relapsed or Refractory
17%
Precision Medicine
16%
Proteogenomics
16%
Acute Promyelocytic Leukemia
16%
Relapsed or Refractory Acute Myeloid Leukemia
12%
Fibroblast Growth factor-2 (FGF-2)
11%
Overall Survival
11%
Adult Patients
11%
Ivosidenib
10%
Differentiation Syndrome
10%
IDH Inhibitors
10%
Drug Resistance
10%
Proteomics
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Quizartinib
9%
FMS-like Tyrosine Kinase 3 (FLT3)
9%
Hematologic Neoplasms
9%
Older Adults
9%
Endometrial Carcinoma
8%
Gilteritinib
8%
Drug Response
8%
BET Inhibition
8%
Transplant Outcomes
8%
Diagnostic Challenge
8%
Clonal Hematopoiesis
8%
Donor-derived
8%
New Therapeutics
8%
Chronic Myeloid Leukemia
8%
Mediastinal Germ Cell Tumor
8%
JAK2V617F
8%
Medicine Treatment
8%
Stepwise Development
8%
High-risk Myelodysplastic Syndrome
8%
Functional Screening
8%
Tumor Cell Proliferation
8%
Calreticulin Gene
8%
Immunosuppressive Therapy
8%
Graft-versus-host Disease (GvHD)
8%
Fibroblast Growth Factor Receptor 3 (FGFR3)
8%
Interleukin-1β
8%
Genomic Profiling
8%
Disease Progression
8%
Phosphoproteomics
8%
Point mutation
8%
European LeukemiaNet
8%
Gastrointestinal Stromal Tumor Cells
8%
Leukemia Microenvironment
8%
Inherited Retinopathy
8%
